trending Market Intelligence /marketintelligence/en/news-insights/trending/927cot9kxkaayoyh5q9qrg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In this list

US FDA approves Shire's hemophilia A treatment in pediatrics

The 2020 U.S. Renewable Energy Outlook

2020 Outlook For Latin American Pay TV, Broadband And Mobile Market

Latin American Pay TV, Broadband Market 2019 Recap

2019 Latin America Multichannel, Broadband And Mobile Market Overview


US FDA approves Shire's hemophilia A treatment in pediatrics

The U.S. FDA approved Shire PLC's Adynovate for the treatment of hemophilia A in pediatric patients under 12 years of age.

The drug was first approved for adults with the genetic blood disorder in November 2015.

The regulator also approved the use of the drug in adult and pediatric patients undergoing surgery.